antihuman ceacam5 cd66e pe  (R&D Systems)

Journal: Oncology Letters

Article Title: Recurrent microsatellite instability-high thymic carcinoma showing complete response to immune checkpoint inhibitor: A case report

doi: 10.3892/ol.2026.15474

Figure Lengend Snippet: Negative immunohistochemical findings of the anterior mediastinal tumor. Tumor cells were negative for (A) CD5, (B) C-kit, (C) TTF-1, (D) CEA and (E) MART-1. TTF-1, thyroid transcription factor-1; CEA, carcinoembryonic antigen; MART-1, melanoma antigen recognized by T cells.

Article Snippet: The following primary antibodies were applied at 36°C for 32–40 min: cytokeratin (cat. no. NCL-L; clone AE1/AE3, Leica, 1:100), p63 (cat. no. NCL-L; clone 7-Jul, Leica, 1:20), c-kit (cat. no. NCL-L-CD117-32; clone EP10, Leica, 1:20), CD5 (cat. no. NCL-L-CD5-4C7; clone 4C7, Leica, 1:200), TTF-1 (cat. no. CMQ 343M-96-RUO; clone 8G7G3/1, Cell Marque, 1:100), CEA (cat. no. 413121; clone COL-1; Nichirei, 1:100), and MART-1 (cat. no. 413381; clone M2-7C10, Nichirei, 1:10).

Techniques: Immunohistochemical staining

Journal: BMC Cancer

Article Title: Individualized drug screening in cholangiocarcinoma using organoid models and patient-derived tumor xenograft

doi: 10.1186/s12885-025-15495-w

Figure Lengend Snippet: Tumor signature molecules expression analysis of CCA PDXs and PDOs. CCA PDXs and PDOs are compared to their primary tumors for tumor signature molecule Ki67, CEA, and P53 IHC staining. Scale bar, 100 μm

Article Snippet: Furthermore, IHC staining for Ki67 (27309-1-AP, Proteintech, 1:4000), CEA (68377-1-Ig, Proteintech, 1:2500), and P53 (60283-2-Ig, Proteintech, 1:2500) was performed for patients’ tumor tissues, PDXs, and PDOs.

Techniques: Expressing, Immunohistochemistry

Journal: Scientific Reports

Article Title: MiR-5095 inhibits proliferation, migration, and invasion of gastric cancer cells by targeting CEACAM5

doi: 10.1038/s41598-025-23669-6

Figure Lengend Snippet: Target gene screening for miR-5095. ( A ) Venn diagram showing the intersection of genes from the GEPIA2, GeneCards, and TargetScan databases. ( B ) The 24 genes regulated by miR-5095 identified through screening. ( C ) Protein-protein interaction network for CEACAM5 from STRING database. (D) Enrichment analysis for the top 26 proteins interacting with CEACAM5.

Article Snippet: Membranes were incubated overnight at 4 °C with primary antibodies against CEACAM5 (1:1000, Proteintech), E-cadherin (1:1000, Proteintech), N-cadherin (1:1000, Proteintech), and Vimentin (1:1000, Proteintech).

Techniques:

Journal: Scientific Reports

Article Title: MiR-5095 inhibits proliferation, migration, and invasion of gastric cancer cells by targeting CEACAM5

doi: 10.1038/s41598-025-23669-6

Figure Lengend Snippet: Validation of CEACAM5 as a target gene of miR-5095. ( A ) mRNA expression of CEACAM5 in tumor tissues ( n = 408) and normal tissues ( n = 211) from the GEPIA2 database. ( B ) Dual-luciferase reporter assay showing the binding sites and fluorescence ratio changes (ns: no significance). Statistical comparisons between groups were performed using unpaired two-tailed t-tests. CEACAM5-WT + miR-5095 mimic vs. CEACAM5-WT + NC mimic group ( P < 0.0001). CEACAM5-Mut + miR-5095 mimic vs. CEACAM5-Mut + NC mimic group ( P = 0.9598). ( C ) Western blotting assay detecting the expression of CEACAM5 in gastric cancer cells ( n = 3). Statistical analysis was performed using unpaired two-tailed t-tests comparing miR-5095 mimics to mimic NC: AGS cells ( P < 0.0001); HGC-27 cells ( P = 0.0002). Representative image shown from three independent experiments. ( D ) RT-qPCR measurement of CEACAM5 expression in gastric cancer cells. Statistical analysis was performed using unpaired two-tailed t-tests comparing miR-5095 mimics to mimic NC: AGS cells ( P < 0.0001); HGC-27 cells ( P = 0.0001). * P < 0.05, ** P < 0.01.

Article Snippet: Membranes were incubated overnight at 4 °C with primary antibodies against CEACAM5 (1:1000, Proteintech), E-cadherin (1:1000, Proteintech), N-cadherin (1:1000, Proteintech), and Vimentin (1:1000, Proteintech).

Techniques: Biomarker Discovery, Expressing, Luciferase, Reporter Assay, Binding Assay, Fluorescence, Two Tailed Test, Western Blot, Quantitative RT-PCR

Journal: Scientific Reports

Article Title: MiR-5095 inhibits proliferation, migration, and invasion of gastric cancer cells by targeting CEACAM5

doi: 10.1038/s41598-025-23669-6

Figure Lengend Snippet: miR-5095 targets CEACAM5 to inhibit gastric cancer cell proliferation, migration, and invasion. ( A ) Western blotting assay detecting CEACAM5 protein expression ( n = 3). OE-NC + miR-5095 mimics vs. OE-NC + NC mimics group (AGS: P = 0.0009, HGC-27: P < 0.0001, unpaired two-tailed t-test). OE-CEACAM5 + miR-5095 mimics group vs. OE-NC + miR-5095 mimics group (AGS: P < 0.0001, HGC-27: P < 0.0001, unpaired two-tailed t-test). Representative image shown from three independent experiments. ( B ) CCK-8 assay showing the change in cell viability ( n = 3). OE-NC + miR-5095 mimics vs. OE-NC + NC mimics group (AGS: P < 0.0001, HGC-27: P < 0.0001, unpaired two-tailed t-test). OE-CEACAM5 + miR-5095 mimics group vs. OE-NC + miR-5095 mimics group (AGS: P < 0.0013, HGC-27: P = 0.0008, unpaired two-tailed t-test). ( C ) Western blotting assay detecting the expression of EMT-related proteins ( n = 3). Statistical analysis was performed using multiple unpaired two-tailed t-tests. OE-NC + miR-5095 mimics vs. OE-NC + NC mimics group: AGS: E-cadherin ( P = 0.0003), N-cadherin ( P < 0.0001), Vimentin ( P = 0.0002); HGC-27: E-cadherin ( P = 0.0006), N-cadherin ( P = 0.0060), Vimentin ( P = 0.0017). OE-CEACAM5 + miR-5095 mimics group vs. OE-NC + miR-5095 mimics group: AGS: E-cadherin ( P = 0.0028), N-cadherin ( P < 0.0001), Vimentin ( P < 0.0001); HGC-27: E-cadherin ( P = 0.0313), N-cadherin ( P < 0.0091), Vimentin ( P = 0.0046). Representative image shown from three independent experiments. Transwell migration ( D ) and invasion ( E ) assay assessing the migration and invasion ability of gastric cancer cells ( n = 3, scale bar = 200 μm). * P < 0.05, ** P < 0.01.

Article Snippet: Membranes were incubated overnight at 4 °C with primary antibodies against CEACAM5 (1:1000, Proteintech), E-cadherin (1:1000, Proteintech), N-cadherin (1:1000, Proteintech), and Vimentin (1:1000, Proteintech).

Techniques: Migration, Western Blot, Expressing, Two Tailed Test, CCK-8 Assay